2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Noile-Immune Biotech Inc.

Company Presentations

Thursday, July 23 Company Presentations 3–Japan

Noile-Immune Biotech Inc.

Company Info

Name /Noile-Immune Biotech Inc.

Address /2-12-10 Shibadaimon, Minato-ku, Tokyo 105-0012, Japan

Website /www.noile-immune.com

Presenter

Name /Hidenobu Ishizaki

Title /President & CEO

Email /ishizaki@noile-immune.com

Telephone /(Work) +81-3-5843-7819

Fax /+81-3-5843-7849

Mobile /+81-80-4345-2999

Company Type

Biotechnology

About the Company

Noile-Immune Biotech Inc., based in Tokyo, is a biotechnology company focused on the development and commercialization of next generation CAR-T therapy with breakthrough platform technology to eradicate cancer cells.

Brief Description of main products or services

Our proprietary PRIME (Proliferation-inducing and migration-enhancing) technology, which express particular combination of IL-7 and CCL19, is designed to enhance anti-tumor potential by enabling infiltration, accumulation, and survival of CAR-T and dendritic cells in coordination with activation of tumor-reactive host T cells and their memory formation. PRIME technology is also able to induce polyclonal T cell immunity against target antigen -positive and -negative tumors (Nature Biotechnology 2018). Because a loss of target molecules is a mechanism of tumor resistance to CAR-T therapy, induction of host T-cell responses specific to endogenous tumor antigens which probably due to epitope spreading, is essential to potentiate the therapeutic effects of the current CAR-T therapies. We established robust IP portfolio and pipelines for solid cancers. Our business model covers research and early clinical development of CAR-T product candidates based on this PRIME technology, followed by out-licensing to pharmaceutical companies. PRIME technology is also available for the platform-based business alliance with other cell therapies such as TCR-T therapy, or gene therapies such as Oncolytic viruses. Our PRIME technology and product candidates are conductive to multiple partnering structures and fields.

In 2018, Takeda Pharmaceutical Company exclusively licensed NIB's original two assets, NIB-102 and NIB-103 for the treatment of various solid tumor indications. Since 2019, NIB has developed steadily in collaboration with leading biotech companies for the co-development of PRIME TCR-T with Adaptimmune Therapeutics, PRIME CAR-T with Autolus Therapeutics, and both PRIME CAR-T and TCR-T products with Legend Biotech.

Contact Person

Name /Hidenobu Ishizaki

Email /ishizaki@noile-immune.com

Phone /(Work) +81-3-5843-7819